Global Complicated Urinary Tract Infection Treatment Scope 2025, Forecast To 2034
26 Mar, 2025
How Has the Complicated Urinary Tract Infection Treatment Market Evolved Historically and What is its Current Size?
The complicated urinary tract infection treatment market has seen considerable growth due to a variety of factors.
• The complex market for urinary tract infection treatments has seen considerable growth in the past few years. Its market size is expected to expand from $8.87 billion in 2024 to $9.47 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%.
The growth during the historical period is likely due to the rising occurrence of urinary tract infections, increasing instances of antibiotic resistance, a growing elderly population, higher hospitalization rates, and enhanced public awareness about UTIs.
What Is The Projected Growth Of The Complicated Urinary Tract Infection Treatment Market?
The complicated urinary tract infection treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The complex market for urinary tract infection treatments is set to experience considerable expansion in the coming years. The market size is predicted to reach $12.13 billion in 2029, with a compound annual growth rate (CAGR) of 6.4%.
This projected growth over the forecast period could be due to an increase in multi-drug resistant pathogens, a heightened concentration on precision medicine, a rise in healthcare expenditure, more frequent use of rapid diagnostic testing, government initiatives, and research funding. Significant trends within this forecast period include improvements to diagnostic methods, increased access to healthcare in developing markets, the introduction of new antibiotics, advancements in diagnostic device technology, and the rise in use of combination treatments.
What Are The Core Factors Supporting Growth In The Complicated Urinary Tract Infection Treatment Market?
The growth of the complex urinary tract infection treatment market is anticipated to be driven by an increasing number of chronic kidney disease (CKD) cases. CKD is a condition that denotes the slow deterioration of kidney functionality over a period of time. A surge in diabetes and hypertension cases, an aging population, lifestyle factors like obesity and smoking are chiefly responsible for the growing prevalence of CKD. The treatment for complex urinary tract infection aids CKD patients by warding off serious infections such as pyelonephritis, which can intensify kidney damage, deteriorate renal function, and accelerate the progression of CKD, thus lowering the chance of further complications and hospitalizations. For example, the Australian Institute of Health and Welfare, an agency run by the Australian government, reported in December 2024 that approximately 21,800 deaths in Australia in 2022 were as a result of CKD. Moreover, Kidney Care UK, a non-profit based in the UK, stated in May 2024 that 40-45,000 premature deaths in the UK occur each year due to CKD. Consequently, the increasing prevalence of chronic kidney diseases fuels the growth of the complex urinary tract infection treatment market.
What Are The Principal Market Segments In The Global Complicated Urinary Tract Infection Treatment Industry?
The complicated urinary tract infection treatment market covered in this report is segmented –
1) By Drug Class: Penicillin And combinations, Quinolones, Cephalosporin, Azoles And Amphotericin B, Nitro furans
2) By Distribution Channel: Hospital Pharmacies, Gynecology And Urology Clinics, Drug stores
3) By Application: Urethritis, Cystitis, Pyelonephritis
Subsegments:
1) By Penicillin And Combinations: Aminopenicillins, Beta-Lactamase Inhibitor Combinations
2) By Quinolones: Fluoroquinolones, Non-Fluoroquinolones
3) By Cephalosporin: First-Generation Cephalosporins, Second-Generation Cephalosporins, Third-Generation Cephalosporins, Fourth-Generation Cephalosporins, Fifth-Generation Cephalosporins
4) By Azoles And Amphotericin B: Triazoles, Imidazoles, Polyene Antifungals
5) By Nitrofurans: Nitrofurantoin, Furazolidone
Which Emerging Market Trends Are Altering The Complicated Urinary Tract Infection Treatment Industry?
Leading firms in the intricate urinary tract infection treatment market are striving to combat antibiotic resistance by inventing innovative antibiotics. This is aimed at boosting treatment effectiveness and dealing with multi-drug resistant pathogens. In treating severe complicated urinary tract infections, targeted antibiotics or antimicrobial agents are used to remove or control infections, especially when the kidney is involved. For example, in February 2024, Allecra Therapeutics, a biopharmaceutical firm based in Germany, received approval from the U.S. Food and Drug Administration (FDA) for the use of EXBLIFEP (cefepime/enmetazobactam) in treating complicated urinary tract infections (cUTIs) in adults. The firm also managed to acquire a five-year marketing exclusivity extension due to the GAIN Act, which encourages the creation of new anti-infective therapies. The study deduced that 79.1% of patients who were treated with cefepime/enmetazobactam achieved a composite response (both clinical cure and microbiological eradication) compared to 58.9% who were treated with piperacillin/tazobactam.
Who Are the Key Players In The Complicated Urinary Tract Infection Treatment Market?
Major companies operating in the complicated urinary tract infection treatment market are:
• Pfizer Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• AstraZeneca PLC
• Fresenius Kabi AG
• GlaxoSmithKline plc
• bioMérieux SA
• Shionogi & Co. Ltd.
• Cipla Limited
• Santen Pharmaceutical Co. Ltd.
• Orchid Pharma Limited
• Melinta Therapeutics Inc.
• Spero Therapeutics Inc.
• Nabriva Therapeutics AG
• Venatorx Pharmaceuticals Inc.
• Recce Pharmaceuticals Ltd
• MerLion Pharmaceuticals Pte. Ltd.
• Entasis Therapeutics Holdings Inc.
• Allecra Therapeutics GmbH
• Allergan Inc.
What Are The Regional Insights Into The Complicated Urinary Tract Infection Treatment Market?
North America was the largest region in the complicated urinary tract infection treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the complicated urinary tract infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.